| Ytd | -50.18% | |
| 1y | -78.39% |
| Open | Prev Close | 2.74 | Low | High | Mkt Cap | 2.63M | |||
| Vol | 0.00 | Avg Vol | 466.11K | EPS | -5.47 | P/E | -0.50 | Forward P/E | -0.79 |
| Beta | 1.43 | Short Ratio | 0.65 | Inst. Own | 3.03% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 2.41 | 200-d Avg | 4.43 | 1yr Est | 7.50 |
ADIL News
GLEN ALLEN, Va., June 16, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adia
LUCID CAPITAL MARKETS analyst Elemer Piros initiates coverage on Adial Pharmaceuticals (NASDAQ:AD
About the TransactionsThe acquisition of Azora was structured as an asset acquisition pursuant to wh
- Acquisition of Azora and concurrent private placement positions the combined company to advance it
GLEN ALLEN, Va., May 11, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial
New U.S. utility patent application targeting patient populations with demonstrated heightened respo
GLEN ALLEN, Va. , April 27, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Ad
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL - Get Free Report) was the recipient of a large decrease i
Demonstration batch production achieves all prespecified test specifications for dissolution, conten
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL - Get Free Report) saw a large growth in short interest du
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL - Get Free Report) was the target of a significant drop in
Company Highlights Advanced Partnering Discussions as AD04 Advances Toward Phase 3 Company Highlight
Regulatory Shift Could Significantly Lower Phase 3 Costs and Accelerate Path Toward NDA Submission f
Adial Pharmaceuticals (NASDAQ: ADIL - Get Free Report) and Kaleido Biosciences (NASDAQ: KLDO - Get F
GLEN ALLEN, Va., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adia
Common Stock Will Begin Trading on Split-Adjusted Basis on February 6, 2026 Common Stock Will Begin
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL - Get Free Report) was the target of a significant decreas
GLEN ALLEN, Va. , Nov. 14, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adi
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL - Get Free Report) was the recipient of a significant decr
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL - Get Free Report) was the recipient of a large decline in
GLEN ALLEN, Va., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adia
Monday saw 825 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Wednesday